Harrisburg Wellness Reporter
SEE OTHER BRANDS

Keeping up with health and wellness news from Pennsylvania

Harrisburg Wellness Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Harrisburg Wellness Reporter.

Press releases published on May 8, 2025

PRN Funding To Attend PHA 2025 Annual Conference

PRN Funding To Attend PHA 2025 Annual Conference

BETHLEHEM, PA, UNITED STATES, May 8, 2025 /⁨EINPresswire.com⁩/ -- PRN Funding is pleased to announce that is now a proud member of the Pennsylvania Homecare Association, as well as attending the PHA 2025 Annual Conference. Established in 1971, the …

Significant Business Results LLC Empowers Business Owners to Grow, Scale and Sell Their Businesses More Effectively

Significant Business Results LLC Empowers Business Owners to Grow, Scale and Sell Their Businesses More Effectively

Discover Proven Strategies from Certified Value Builder Advisor Franne McNeal to Build a Profitable, Scalable Business That Runs Without You BRYN MAWR, PA, UNITED STATES, May 8, 2025 /⁨EINPresswire.com⁩/ -- Franne McNeal, President of Significant Business …

Rosemark to Showcase Home Care Software at 2025 PHA Conference

Rosemark to Showcase Home Care Software at 2025 PHA Conference

With Pennsylvania’s home care agencies facing increasing regulatory demands, how can technology simplify operations and boost efficiency? Rosemark will answer! PA, UNITED STATES, May 8, 2025 /⁨EINPresswire.com⁩/ -- With Pennsylvania’s home care agencies …

Kymanox® Announces Low Volume Manufacturing Capabilities Supporting Human Clinical Studies

Kymanox® Announces Low Volume Manufacturing Capabilities Supporting Human Clinical Studies

The company strengthens its end-to-end service offerings with GMP-compliant manufacturing for medical devices and device constituents of combination products KING OF PRUSSIA, PA, UNITED STATES, May 8, 2025 /⁨EINPresswire.com⁩/ -- Kymanox®, a leading …

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

-- Company delivers on mission to transform women’s health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) -- ATLANTA, May 08, …

Nova Leap Health Corp. Posts Q1 2025 Results

Nova Leap Health Corp. Posts Q1 2025 Results

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, May 08, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, is …

VitalHub Reports First Quarter 2025 Results

VitalHub Reports First Quarter 2025 Results

Annual Recurring Revenue (ARR)⁽¹⁾ up 54% YoY to $73.7 million Total Revenue up 42% YoY to $21.7 million Adjusted EBITDA⁽¹⁾ up 39% YoY to $5.6 million TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX: …

Tarsus to Participate in Upcoming Investor Conferences

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the following upcoming investor conferences: Bank of America Securities 2025 Health Care Conference on …

Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering

Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering

Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally …

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and …

BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025

BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025

MELVILLE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced …

Theriva Biologics Announces Closing of $7.5 Million Public Offering

Theriva Biologics Announces Closing of $7.5 Million Public Offering

ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, …

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate …

BioSyent Schedules First Quarter Earnings Release for May 15, 2025

BioSyent Schedules First Quarter Earnings Release for May 15, 2025

MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2025 on Thursday, May 15, 2025 after market hours. A presentation …

Galecto Reports First Quarter 2025 Operating and Financial Results

Galecto Reports First Quarter 2025 Operating and Financial Results

BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter …

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson’s disease in Q4 2025 Strengthened balance sheet with recent financing Advancing innovative POZ Platform across multiple therapeutic modalities Two new seasoned …

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results …

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025 Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for …

PacBio Announces First Quarter 2025 Financial Results

PacBio Announces First Quarter 2025 Financial Results

MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results:   Q1 2025 Q1 2024 Revenue $37.2 million $38.8 million Instrument revenue $11.0 million …

Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service